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A B S T R A C T
Retinopathy and nephropathy are common late type 1 diabetes mellitus (T1D) complications. In this study we investi-
gated whether individual differences in 4 candidate genes significantly contribute to development and progression of late
complications in T1D patients. We examined 121 patients for the presence of diabetic retinopathy and nephropathy. We
genotyped variants in vitamin D receptor (VDR) and tumor necrosis factor (TNF) genes in 47 patients and in NeuroD1
and interleukin-1 receptor 1 (IL1R1) genes in 35 patients. Diabetic retinopathy had 66 (55%) patients after a median of
13.0 years after diagnosis. Diabetic nephropathy had 14 (11.66%) patients, all of whom had already developed retino-
pathy. A significant correlation between the degree of diabetic retinopathy and mean microalbuminuria (MA) value has
been found (c2=54.18, p<0.001). After correcting for duration of disease, only the VDR gene BsmI genotypes showed sig-
nificant association with cumulative prevalence of diabetic retinopathy, while no investigated genetic polymorphysms
could reliably predict diabetic nephropathy.
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Introduction
Diabetes mellitus comprises several different clinical
syndromes, which have in common chronic hyperglyce-
mia and metabolic disorders, which later lead to ocular,
renal, neuronal and vascular complications1. Microangio-
pathy, as a chronic diabetic complication, involves partic-
ularly small retinal, neuronal, and glomerular vessels2.
Epidemiological data show that diabetic retinopathy and
nephropathy are closely correlated. About 90% of pa-
tients with a history of more than 20 years of type 1 dia-
betes mellitus (T1D) develop diabetic retinopathy (15–20%
develop blindness) and 25–40% develop diabetic nephro-
pathy3,4. Early onset of diabetic retinopathy is often asso-
ciated with nephropathy, although the mechanism is still
not fully understood5. However, other authors described
cases of quite advanced renal dysfunction with modest or
even inexistent retinal signs of diabetic retinopathy6,7.
T1D is complex disease and has a strong genetic com-
ponent8. Vitamin D, tumor necrosis factor alpha (TNF-a)
and interleukin (IL)-1 may play a critical role in the
pathogenesis of inflammatory and autoimmune disease
like T1D9–11. All of them are involved in immune reac-
tions in the organism. Vitamin D has immunosuppressi-
ve effect exerted via promotion of monocyte differentia-
tion and inhibition of lymphocyte proliferation and secre-
tion of cytokines, such as IL-2, interferon-g and IL-129.
TNF-a can be cytotoxic for b-cells supported by both IL-1
and interferon-g10. IL-1 in very low concentrations has
cytotoxic effects on islets of Langerhans11.
The effects of vitamin D are mediated by a nuclear re-
ceptor (VDR) that acts as a ligand-activated transcrip-
99
Received for publication December 7, 2008
tion factor12. The VDR gene located on chromosome
2q14, has several frequently studied single nucleotide
polymorphisms (SNP). These are FokI G/A change in
exon 2, TaqI T/C change in exon 9, BsmI A/G, Tru9I G/A
and ApaI G/T changes in intron 813. FokI occurs at the
first start codon in exon 2 and changes the translation
initiation site resulting in a three amino acids shorter
protein which is considered to be more active than the
wild-type14.
TNF-a is coded by TNF gene located on chromosome
6 in the HLA region class III15. Two promoter SNPs at
positions –308 G/A and –238 G/A of the TNF gene have
been commonly studied. The polymorphisms within the
TNF promoter region may affect transcription factor
binding sites resulting in TNF-a differential expression,
which can modulate the risk to T1D16. IL-1 type 1 recep-
tor (IL1R1) is found on most cells including T lympho-
cytes and b cells17. IL1R1 gene maps to chromosome 2
(2q12-22)18. Several IL1R1 gene SNPs like HinfI G/A,
PstI G/A, AluI T/C in the promoter region and PstI-e C/T
in exon 1B have been frequently studied19–21.
Human NeuroD1 gene (known as BETA2 or NeuroD/
BETA2) has been mapped on the chromosome 2 (2q32).
NeuroD1 is a transcription factor expressed in pancre-
atic endocrine, intestine and brain cells22. It activates the
transcription of the insulin gene in pancreatic b cells22. It
is known that MwoI G/A polymorphism, located in codon
45 of the exon 2 of the NeuroD1 gene, leads to Ala/Thr
substitution of protein23.
The aim of this study was to investigate the associa-
tion between diabetic retinopathy and nephropathy (in-
cipient and clinical) in patients with T1D and to attempt
to predict the development of those complications by as-
sociating them to the variants in the recently described
candidate genes – VDR, TNF, NeuroD1 and IL1R1.
Materials and Methods
A total of 141 patients with T1D were included in the
present study. Nine patients were excluded because they
had argon laser photocoagulation previously done, 3 be-
cause of terminal renal insufficiency, 4 had urinal tract
infection and 5 had poor metabolic disorder regulation
(HbA1c >9%) (Figure 1).
Among 120 patients that remained in the study, 65
(54.2%) were men and 55 (45.8%) women. The mean age
of onset of diabetes type I was 17.2±9.3 years, and mean
duration of the illness was 13.9±9.1. In the study group
the mean age was 32.2±13.9 years for men, and 29.2±13.8
years for women, with the median of 13 years of fol-
low-up after diagnosis.
Labotarotory exams included glycosylated hemoglo-
bin (HbA1c-assay used on the Dimension clinical chemis-
try system) and creatinine clearance. These parameters
were used only as orientation of metabolic regulation
and renal status and were not used for other analyses
performed in this study. To assess the development of
retinopathy, all patients underwent through ophthalmo-
logical examination that included direct and indirect
fundus examination with pupils previously dilated (tro-
picamide 1%) and 30° color fundus single-field photogra-
phy (fundus camera Zeiss FF 450 plus IR-Germany). If
any diabetic changes were detected, data were collected
from the examination of the eye with the worse results.
According to ophthalmological findings all patients were
grouped into three different groups: (i) group without di-
abetic retinopathy, (ii) group with nonproliferative dia-
betic retinopathy and (iii) group with proliferative dia-
betic retinopathy.
To assess the development of diabetic nephropathy
(in patient without signs of urinal tract infection from
urine sediment examination) the mircroalbuminuria (MA)
and the proteinuria was tested by turbidimetric method
(ARCHITECT cSYSTEMS – Abbot Diagnostics, USA)
twice during 15 days. We used MULTIGENT immuno-
assay for the quantization of albumins and U-Pro assay
for the quantization of proteins. The mean result value
30 mg/24 hour was considered as a sign of MA (incipient
nephropathy) and 0.5 g/24 hours as a sign of proteinuria
(clinical or evident nephropathy). Patients were divided
according to turbidimetric immunoassay results in three
groups: (i) no MA (albumin <30 mg/24h urine), (ii) MA
(albumin 30–300 mg/24h urine) and (iii) clinical albumi-
nuria (>300 mg/24h urine). According to turbidimetric
U-Pro assay results patients were also subdivided in two
groups: without diabetic nephropathy (proteinuria<0.5
g/24 hours) and with diabetic nephropathy (proteinuria
0.5 g/24 hours).
We have genotyped VDR and TNF candidate genes in
47 patients and NeuroD1 and IL1R1 genes in 35 pa-
tients. Genomic DNA was extracted from peripheral
blood leucocytes using the Perfect gDNA kit (Eppendorf,




























Fig. 1. Flowchart of patients included in the study.
Hamburg, Germany). Genotypes for five gene SNPs in
VDR gene (BsmI, ApaI, TaqI, FokI and Tru9I), two gene
SNPs in TNF gene (–308 and –238), four gene SNPs in
IL1R1 gene (PstI, HinfI, AluI, and PstI-e) and one gene
SNP in NeuroD1 gene (MwoI) were identified by PCR
followed by RFLP analysis, according to previous re-
ports14,19,26–29. Genotypes for the polymorphisms in the
VDR and IL1R1 genes were designated with a capital let-
ter for the absence of a restriction site and with a lower-
case letter for its presence. Therefore, the genotypes are
as follows: BsmI=BB, bb (homozygous for the absence or
presence of the cut site, respectively) and Bb (heterozy-
gous); ApaI=AA, aa, Aa; TaqI=TT, tt, Tt; FokI=FF, ff,
Ff; Tru9I=UU, uu, Uu; PstI=PP, pp, Pp; HinfI=HH, hh,
Hh; AluI=AA, aa, Aa, PstI-e=P’P’, p’p’, P’p’. Genotypes
for the TNF gene and NeuroD1 gene SNPs were desig-
nated with GG for guanine homozygotes, AA for adenine
homozygotes and AG for adenine/guanine heterozygotes.
The aim was to correlate different variants to progre-
ssion of complications in T1D and to determine »geno-
type relative risks« for development of complications of
T1D.
Statistical analysis was done with SPSS/PC+ pro-
gram. ANOVA, c2-test, Duncan test and Man-Whitney
U-test were used to compare data.
Results
Diabetic retinopathy was found in 66 (55%) patients.
Forty two (63.63%) had nonproliferative and 24 (36.37%)
had proliferative diabetic retinopathy (Figure 1).
MA was absent in 78 (65%) patients, present in 28
(23%) patients and persistent in 14 (12%) patients. Tur-
bidimetric immunoassay results in different diabetic re-
tinopathy groups are shown in Table 1. There was statis-
tically significant correlation between MA and the degree
of diabetic retinopathy (c2=54.18, p<0.001). Greater de-
gree of diabetic retinopathy is correlated with higher in-
cidence of MA and vice versa. Particularly high positive
correlation was found in group with proliferative diabetic
retinopathy.
MA mean value in the group of patients without diabe-
tic retinopathy was 23.5±44,6 mg/24h urine, 68.9±117.9
mg/24h urine in the group with nonproliferative diabetic
retinopathy and 899.1±1300 mg/24h urine in the group
of patients with proliferative diabetic retinopathy. There
was statistically significant difference in MA mean val-
ues between three diabetic retinopathy groups (c2=39.5,
p<0.001). Patients with normal fundus findings had nor-
mal MA mean value, while in more advanced stages of di-
abetic retinopathy MA mean value was higher.
In the group of patients without diabetic retinopathy
there were no patients with diabetic nephropathy, while
2 (4.8%) patients in the group with nonproliferative dia-
betic retinopathy and 12 (50%) patients in the group
with proliferative diabetic retinopathy had diabetic ne-
phropathy. There was statistically significant correlation
of diabetic nephropathy with grade of diabetic retino-
pathy (c2=38.72, p<0.001). Diabetic nephropathy was
most commonly found in patients with proliferative dia-
betic retinopathy.
Proteinuria mean value in the group of patients without
diabetic retinopathy was 0.08±0.09 g/24h urine, 0.16±0.21
g/24h urine in the group with nonproliferative diabetic
retinopathy and 1.41±2.0 g/24h urine in the group of pa-
tients with proliferative diabetic retinopathy. There was
statistically significant difference in proteinuria mean
values between three diabetic retinopathy groups (c2=
27.34, p<0.001). Greatest mean value of proteinuria was
found in patients with proliferative diabetic retinopathy.
The longer the duration of T1D, the higher the proba-
bility of developing higher grade diabetic retinopathy, be-
cause the mean duration of T1D was 7.4±5.6 years in the
group without diabetic retinopathy, 17.4±7.9 years in the
group with nonproliferative diabetic retinopathy, and
22.4±6.8 years in the group with proliferative diabetic
nephropathy (F=49.84, p<0.001).
Predictably, cumulative prevalence of MA increases
with the duration of T1D. In the group of patients with
no MA, mean duration was 11.2±8.3 years, in the group
with MA it was 17.0±8.9 and in the group with macro-
albuminuria was 21.0±6.5 years. Analysis of variance
showed statistically significant difference in diabetes du-
ration among three groups (F=13.81, p<0.001) (Figure
2). There was also statistically significant difference in
diabetes duration between the group with diabetic ne-
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TABLE 1
DISTRIBUTION OF PATIENTS ACCORDING TO GRADE OF DIA-












47 7 0 54
Nonproliferattive
diabetic retinopathy
26 14 2 42
Proliferative diabetic
retinopathy
5 7 12 24

















Fig. 2. Cumulative prevalence of various types of diabetic
retinopathy according to the duration of diabetes type 1.
phropathy (21.4±6.0 years) and the group without dia-
betic nephropathy (12.8±8.9 years) (t=4.89, p<0.001).
(Figure 3).
These relationships between duration of T1D and cu-
mulative prevalence of complications, shown in figures 2
and 3, were very helpful as they were used to standardize
the subsequent cumulative prevalence according to dif-
ferent genotypes by duration of disease. Table 2 shows
that after correcting for duration of disease, only the
BsmI VDR genotypes showed significant association with
cumulative prevalence of retinopathy (p<0.05), while no
investigated genetic polymorphysms could reliably pre-
dict nephropathy as none of the observed differences for-
mally approached statistical significance.
Discussion
Diabetic retinopathy is the most common and most
difficult eye complication of diabetes and is the leading
cause of blindness in the active population4. Ophthalmol-
ogist has the possibility of direct examination of the
blood vessels, which permits him not only to treat the eye
but also to participate actively in prevention, diagnostics
and treatment of late diabetic complications. Detection
of grades that are still reversible is of crucial importance,
because appropriate therapy can significantly postpone
or even prevent the onset of irreversible diabetic renal
changes. We used fundoscopy and turbidimetric method
as most common diagnostic methods, even though much
sophisticated methods (as fluorescein angiography and
renal biopsy) for determination of diabetic retinopathy
and nephropathy are now available. We considered fun-
doscopy as relevant because some authors have con-
firmed that 85% of findings obtained by direct or indirect
fundoscopy on dilated pupil were the same as those ob-
tained by fundus multi-field photography30. In support,
we found diabetic retinopathy in 55.0% of patients and
diabetic nephropathy in 10.8% of patients, which is near
to results found in one previous study where 64.3% of pa-
tients had diabetic retinopathy and 14.2% diabetic nep-
hropathy with the similar duration of T1D31.
Our data show that there is statistical correlation of
MA with diabetic retinopathy grade. There was 50%





















Fig. 3. The incidence of microalbuminuria according to the
duration of diabetes type 1.
TABLE 2
EFFECTS OF DIFFERENT GENOTYPES IN POLYMORPHYC REGIONS OF THE FOUR CANDIDATE GENES ON CUMULATIVE
PREVALENCE OF COMPLICATIONS OF T1D










FF 13 (27.7%) 9 mths 6/13 (46.2%) 4/13 (30.8%) *N.S.
Ff 24 (51.1%) 8.5 mths 9/24 (37.5%) 6/24 (25.0%) **N.S.
ff 10 (21.3%) 6 mths 4/10 (40.0%) 4/10 (40.0%)
Total 47 (100%)
2. VDR-TaqI
TT 18 (38.3%) 9.5 mths 7/18 (38.9%) 5/18 (27.8%) *N.S.
Tt 20 (42.6%) 8 mths 8/20 (40.0%) 6/20 (30.0%) **N.S.
tt 9 (19.1%) 6 mths 4/9 (44.4%) 3/9 (33.3%)
Total 47 (100%)
3. VDR-BsmI
BB 7 (14.9%) 7 mths 2/7 (28.6%) 1/7 (14.3%) <0.05
Bb 26 (55.3%) 8 mths 10/26 (38.5%) 8/26 (30.8%) **N.S.
bb 14 (29.8%) 9 mths 7/14 (50.0%) 5/14 (35.8%)
Total 47 (100%)
4. VDR-Tru9I
UU 34 (72.3%) 9 mths 15/34 (44.1%) 12/34 (35.3%) *N.S.
Uu 12 (25.5%) 8 mths 3/12 (25.0%) 2/12 (16.7%) **N.S.
uu 1 (2.1%) 7 mths 1/1 (100%) 0/1 (0%)
Total 47 (100%)
probability that patient in the group with proliferative
diabetic retinopathy had persistent MA and 79% proba-
bility of having MA. Furthermore, patients without dia-
betic retinopathy did not have MA in 24 hour urine and
the difference in MA between patients with and without
diabetic retinopathy was statistically significant. In our
study, diabetic nephropathy was commonly found in pa-
tients with proliferative diabetic retinopathy, while was
extremely rare in patients without diabetic retinopathy.
This is in concordance with some previous studies where
patients with T1D and proliferative diabetic retinopathy
had five times grater risk of having proteinuria32. This
underscores the importance of turbidimetric test in 24
hour urine, especially in patients who have developed di-
abetic retinopathy. For example, in the present study, in
case of 14 patients with nonproliferative diabetic retino-
pathy and 7 patients with proliferative diabetic retino-
pathy, early detection of incipient diabetic nephropathy
would be done by turbodimetric imunoassay and conse-
quently would get an adequate and timely treatment.
There was an obvious direct correlation between diabetic
nephropathy and proliferative diabetic retinopathy, what
was also reported in WESDR study33.
After correcting for duration of disease, only the BsmI
VDR genotypes showed significant association with cu-
mulative prevalence of retinopathy in the patients of
South Croatia. In the two separate studies of the VDR ge-
ne in the French population, FokI and TaqI SNPs associ-
ations with diabetic retinopathy have been suggested34,35.
However, Capoluongo et al did not find FokI and BsmI
SNPs associations with diabetes complications in the
Italian population36.
K. Bu}an et al.: Gene polymorphisms and T1D complications, Coll. Antropol. 33 (2009) Suppl. 2: 99–105
103
5. TNF-238I
AA 0 (0%) – – – *N.S.
AG 4 (8.5%) 6.5 mths 2/4 (50.0%) 1/4 (25.0%) **N.S.
GG 43 (91.5%) 9 mths 17/43 (39.5%) 13/43 (30.23%)
Total 47 (100%)
6. TNF-308I
AA 4 (8.5%) 7 mths 1/4 (25.0%) 1/4 (25.0%) *N.S.
AG 12 (25.6%) 10 mths 7/12 (58.3%) 4/12 (33.3%) **N.S.
GG 31 (66.0%) 8 mths 11/31 (35.5%) 9/31 (29.0%)
Total 47 (100%)
7. NeuroD1
AA 7 (20.0%) 7 mths 2/7 (28.6%) 1/7 (14.3%) *N.S.
AG 18 (51.4%) 10 mths 10/18 (55.6%) 7/18 (38.9%) **N.S.
GG 10 (28.6%) 11 mths 3/10 (30.0%) 3/10 (30.0%)
Total 35 (100%)
8. IL1R1-PstI
pp 1 (2.9%) 13 mths 0/1 (0%) 0/1 (0%) *N.S.
Pp 15 (42.9%) 9 mths 9/15 (60.0%) 6/15 (40.0%) **N.S.
PP 19 (54.3%) 10 mths 6/19 (31.6%) 5/19 (26.3%)
Total 35 (100%)
9. IL1R1-HinfI
hh 1 (2.9%) 13 mths 0/1 (0%) 0/1 (0%) *N.S.
Hh 15 (42.9%) 9 mths 9/15 (60.0%) 6/15 (40.0%) **N.S.
HH 19 (54.3%) 10 mths 6/19 (31.6%) 5/19 (26.3%)
Total 35 (100%)
10. IL1R1-AluI
aa 6 (17.1%) 11 mths 2/6 (33.3%) 2/6 (33.3%) *N.S.
Aa 23 (65.7%) 10 mths 11/23 (47.8%) 8/23 (34.8%) **N.S.
AA 6 (17.1%) 7.5 mths 2/6 (33.3%) 1/6 (16.7%)
Total 35 (100%)
11. IL1R1-Pst-e
P’P’ 4 (11.4%) 9.5 mths 2/4 (50.0%) 1/4 (25.0%) *N.S.
P’p’ 21 (60.0%) 8 mths 9/21 (42.9%) 7/21 (33.3%) **N.S.
P’p’ 10 (28.6%) 13 mths 4/10 (40.0%) 3/10 (30.0%)
Total 35 (100%)
The duration of T1D is in strong correlation with de-
velopment of diabetic nephropathy. In more recent stud-
ies it was found that 30–45% microalbuminuric patients
progress to proteinuria over 10 years25. Understanding
that the mean time of diabetes duration in mentioned
groups does not mean coincident onset of functional dis-
orders, that time lap implies the need for MA testing in
order to start the adequate treatment as soon as possible.
Similarly, significant difference in T1D duration was
found among groups with various grade of diabetic re-
tinopathy. We have found nonproliferative diabetic re-
tinopathy in only 1 (4%) patient among 25 patients with
diabetes duration up to 5 years, while other authors
found 0–6% of their patients to have developed diabetic
retinopathy within first five years31,37–39. Proliferative di-
abetic retinopathy is rare until 5 years diabetes duration,
and afterwards it begins to be more frequent. The 4-year
incidence of developing proliferative retinopathy in the
WESDR younger-onset group increased from 0% during
the first 5 years to 27.9% during years 13–14 of diabetes.
After 15 years, the incidence of developing proliferative
diabetic retinopathy remained stable38,40,41. We had 42%
of patients with proliferative diabetic retinopathy in the
group of patients with over 15 years of diabetes duration,
while Eriksen et al. reported 60%42. Barreta et al. repor-
ted 28.6% of patients with proliferative diabetic retino-
pathy after 26 years of diabetes, Klein et al. reported
51.2% after 20 years and 67% after 35 years, and Karma
et al. reported 50% after 20 years31,33,43. In present study
all patients with over 26 years of diabetes duration had
proliferative diabetic retinopathy.
Among all patients included in this study, 28 (23.3%)
had MA, and 14 (50%) of them were on diabetic treat-
ment for 15 to 25 years. Other authors reported from
5–22% of patients having MA, depending on the dura-
tion of diabetes, detecting method and patients chara-
cteristics44,45. Many authors report that MA is rare in
first 5 years of diabetes. Persistent MA was found in pa-
tients over 10 years of diabetes, with greatest incidence
(27.8%) in patients with 21–25 years of diabetes treat-
ment, which was the same as other authors previously
reported24,45.
The incidence of nephropathy was getting higher with
the duration of diabetes. Clinical diabetic nephropathy
was not found in patients with less than 10 years of dia-
betes treatment, while 9 (24.3%) had it and have had dia-
betes for 16–25 years. Other authors found proteinuria
in 15–40% of patients with T1D, with a peak incidence
around 15–20 years of diabetes duration25,46.
In conclusion, there was a statistically significant cor-
relation between MA and the degree of diabetic retino-
pathy, where higher MA is mostly accompanied by higher
grade diabetic retinopathy. Proteinuria followed the sa-
me trend. The highest levels of albumine in 24 hour
urine were found in patients with proliferative diabetic
retinopathy. Therefore, the detection of MA, as an indica-
tor of developing clinically evident diabetic nephropathy
in patients with T1D, is the most adequate way of discov-
ering early pathological renal changes in patients with
high risk of development of diabetic nephropathy. Gen-
erally, the investigated polymorphysms in the four candi-
date genes did not show strong effects on the develop-
ment of late complications of T1D and large sample sizes
will be required to detect more subtle effects.
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POVEZANOST RETINOPATIJE I NEFROPATIJE U PACIJENATA SA DIJABETESOM MELITUSOM
TIP 1 SA GENSKIM POLIMORFIZMIMA RECEPTORA ZA VITAMIN D, TNF, NEURO-D I IL-1
RECEPTOR
S A @ E T A K
Retinopatija i nefropatija su ~este kasne komplikacije dijabetesa tip 1 (engl. Type 1 diabetes -T1D). U ovoj smo
studiji ispitali da li pojedina~ne razlike ~etiriju gena kandidata zna~ajno utje~u na razvoj i progresiju kasnih kom-
plikacija T1D. U ovu smo studiju uklju~ili 121 pacijenta kojima je bila tra`ena prisutnost dijabeti~ke retinopatije i
nefropatije. Kod 47 pacijenata ispitali smo prisutnost genotipskih varijanti za receptor vitamina D (engl. Vitamin D re-
ceptor-VDR) i faktor tumorske nekroze (Tumor necrosis factor-TNF), a gene za Neuro D1 i receptor 1 interleukina-1
(engl. Interleukin-1 receptor 1-IL1R1) u 35 pacijenata. Dijabeti~ku retinopatiju su imali 66 (55% pacijenata nakon
medijana od 13.0 godina nakon dijagnoze. Dijabeti~ku nefropatiju je imalo 14 (11.66%) pacijenata, a oni su svi ve} imali
prethodno razvijenu retinopatiju. Na|ena je zna~ajna korelacija izme|u stupnja dijabeti~ke retionpatije i srednje mi-
kroalbuminurije (MA) (c2=54,18, p<0,001). Nakon korekcije u odnosu na duljinu bolesti na|eno je da samo gen za VDR
zvan Bsml, ima zna~aju korelaciju sa kumulativnom prevalencijom dijabeti~ke retinopatije, dok niti jedan ispitani gen-
ski polimorfizam nije mogao sa sigurno{}u predvidjeti nastanak dijabeti~ke retinopatije.
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